Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

BACKGROUND: Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant, 40% reduction in relative ri...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gaziano, J. Michael, Cincotta, Anthony H., Vinik, Aaron, Blonde, Lawrence, Bohannon, Nancy, Scranton, Richard
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2012
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3541616/
https://ncbi.nlm.nih.gov/pubmed/23316290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.112.002279
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki